AKAO Quote Trading Chart Achaogen

$ Last:

2.23% Change Percent:

$0.106 Open:

$0.11 Previous Close:

$0.19 High:

$0.102 Low:

47,627,225 Volume:

12/31/1969 07:00:00 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Stock Date	Open Price	Close Price	High	Low	Volume
2019-04-25	0.106	0.11	0.19	0.102	47,627,225
2019-04-24	0.118	0.1076	0.13	0.1034	9,541,741
2019-04-23	0.1593	0.1372	0.1596	0.13	3,999,234
2019-04-22	0.175	0.1521	0.175	0.151	4,770,823
2019-04-19	0.1775	0.1748	0.179	0.163	2,846,546
2019-04-18	0.1775	0.1748	0.179	0.163	2,782,220
2019-04-17	0.178	0.184	0.195	0.1721	7,429,554
2019-04-16	0.16	0.1627	0.22	0.159	26,542,390
2019-04-15	0.2216	0.1557	0.33	0.145	34,663,959
2019-04-12	0.46	0.495	0.5198	0.46	1,100,135
2019-04-11	0.5072	0.486	0.53	0.48	489,077
2019-04-10	0.5061	0.5072	0.54	0.489	1,617,166
2019-04-09	0.48	0.516	0.535	0.48	1,323,422
2019-04-08	0.545	0.52	0.545	0.5011	1,403,821
2019-04-05	0.55	0.5381	0.569	0.5175	1,849,080
2019-04-04	0.5188	0.52	0.5999	0.49	4,172,340
2019-04-03	0.43	0.4796	0.50	0.4201	2,120,259
2019-04-02	0.4369	0.4338	0.4435	0.415	1,839,548
2019-04-01	0.4682	0.4369	0.47	0.4201	1,173,159
2019-03-29	0.41	0.4563	0.4849	0.40	2,293,986

Stock Information

Achaogen Company Name:

AKAO Stock Symbol:

NASDAQ Market:

Achaogen Website:

AKAO Quote Trading Chart Achaogen

Get AKAO Alerts

News, Short Squeeze, Breakout and More Instantly...

AKAO - Achaogen, Inc. Announces Results of Auction for Substantially All Company Assets

SOUTH SAN FRANCISCO, Calif., June 06, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc., a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, announced today it has reached agreements to sell substan...
AKAO - Achaogen Plans for Near-Term Sale Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

SOUTH SAN FRANCISCO, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, announced today that it has filed a volun...
AKAO - Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

-- ZEMDRI’s once-daily 30-minute infusion facilitating usage in the outpatient setting -- -- Company’s recent restructuring aimed at conserving capital to continue assessment of strategic alternatives -- -- Conference call today at 4:30 p.m. Eastern Time -- SOUTH S...